SJS Investment Consulting
RPRX icon

SJS Investment Consulting’s Royalty Pharma RPRX Stock Holding History

SJS Investment Consulting’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$23.9K Hold
409
– – ﹤0.01% 934
2026
Q2 		$22.9K Buy
409
+92
+29% +$4.79K ﹤0.01% 745
2026
Q1 		$15.2K Buy
317
+211
+199% +$9.24K ﹤0.01% 730
2025
Q4 		$4.1K Sell
106
-419
-80% -$16K ﹤0.01% 987
2025
Q3 		$18.5K Buy
525
+419
+395% +$15.2K ﹤0.01% 539
2025
Q2 		$3.82K Hold
106
– – ﹤0.01% 437
2025
Q1 		$3.3K Hold
106
– – ﹤0.01% 557
2024
Q4 		$2.7K Hold
106
– – ﹤0.01% 593
2024
Q3 		$3K Hold
106
– – ﹤0.01% 626
2024
Q2 		$2.8K Hold
106
– – ﹤0.01% 589
2024
Q1 		$3.22K Buy
+106
New +$3.12K ﹤0.01% 571

Other funds holding RPRX

Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Royal London Asset Management
Royal London Asset Management United Kingdom $54.5B AUM 31.87% 1-Year Est. Return

SJS Investment Consulting's RPRX Position: Q3 2026 in Review

SJS Investment Consulting held its Royalty Pharma (RPRX) position steady in Q3 2026 at 409 shares worth $23.9K. The position accounts for ﹤0.01% of the portfolio, ranked #934.

SJS Investment Consulting first reported a position in RPRX in Q1 2024 and has held it in 11 quarters since. 485 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • SJS Investment Consulting held 409 shares of Royalty Pharma worth $23.9K as of Q3 2026.
  • SJS Investment Consulting left its Royalty Pharma share count unchanged in Q3 2026.
  • Royalty Pharma made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #934 holding.
  • SJS Investment Consulting first reported a position in Royalty Pharma in Q1 2024 and has held it in 11 quarters since.
  • 485 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.